Serum Concentrations of Vascular Endothelial Growth Factor in Infants Treated With Ranibizumab for Retinopathy of Prematurity
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2018
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- 10 Oct 2018 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 25 Apr 2018 Planned End Date changed from 1 Dec 2018 to 30 Jun 2018.